Last update:

Other news

Other

Most donor-conceived children are told of their biological origins, research reveals

Four out of five parents tell their donor-conceived children about their biological origins, according to new research out of Waipapa Taumata Rau, University of Auckland.

Other

Process for dealing with sexual misconduct by UK doctors requires major reform, say experts

The current process for managing sexual misconduct perpetrated by doctors in the UK requires major reform, say experts in The BMJ.

Other

Beyond the band-aid: A career opportunity as a school nurse

When thinking of nurses, the image that most often comes to mind is one of bustling hospital corridors, emergency rooms, and bedside care. However, one vital role that frequently goes unnoticed is that of the school nurse—a ...

Psychology & Psychiatry

Escape rooms provide fun, help teach anatomy concepts creatively

Virtual escape rooms focusing on anatomy education concepts provide medical students with a fun, creative and challenging way to engage with classroom material, improve their critical thinking, and identify gaps in knowledge. ...

Other

ALS care: Global differences in life support decisions

A new study reveals striking international differences in how doctors approach the sensitive issue of tracheostomy invasive ventilation (TIV) for patients with amyotrophic lateral sclerosis (ALS). Cultural norms and health ...

Other

US health boss Kennedy calls medical journals corrupt

US Health Secretary Robert F. Kennedy Jr has attacked major medical journals, accusing them of collaborating with the pharmaceutical industry and threatening to bar government scientists from publishing in them.

Other

Regeneron to buy 23andMe out of bankruptcy for $256 mn

Regeneron Pharmaceuticals said Monday it will buy genetic testing company 23andMe out of bankruptcy for $256 million, a deal that provides the US biotech company with data on millions of clients.

Other

Pfizer buys biotech firm Seagen for $43 billion

US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.